Payment overview · 2025
General Payments
$753.74
25 reported records · 6 companies
Healthcare provider profile · identity verified
John H. Mitchell, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BREA, CA · NPI 1225024912
Verified facts
What the public records show
CMS Open Payments records show John H. Mitchell, M.D. received $753.74 in general payments during 2025 across 25 reported records.
Amgen Inc. accounted for 56.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Aplenzin, Jardiance, Kerendia, Mounjaro, Synthroid, Xyosted.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 225 claims for Synthroid by this doctor in 2024.
Antares Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYOSTED as an associated drug or biological on 18015 records involving 7619 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Xyosted by this doctor in 2024.
Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APLENZIN as an associated drug or biological on 9096 records involving 3309 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Aplenzin by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $427.94 | 56.8% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $161.53 | 21.4% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $86.99 | 11.5% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.90 | 4.0% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $24.73 | 3.3% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.65 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $753.74 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $427.94 | 12 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $174.20 | 8 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $136.20 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $136.20 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $46.18 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $40.81 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.81 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.90 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $25.33 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $22.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| APLENZIN aplenzin |
2025 | Aplenzin | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 101 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 192 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 225 | exact normalized | Medicare Part D |
| XYOSTED xyosted |
2025 | Xyosted | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
225 | 61 |
| Antares Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | XYOSTED open payments reported associated product |
CMS Open Payments — General Payments 18015 supporting records · 7619 recipient NPIs · example record 1235880452 |
Xyosted · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | APLENZIN open payments reported associated product |
CMS Open Payments — General Payments 9096 supporting records · 3309 recipient NPIs · example record 1239973605 |
Aplenzin · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
101 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
192 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Synthroid | Levothyroxine Sodium | 225 | 61 |
| Mounjaro | Tirzepatide | 192 | 22 |
| Repatha Sureclick | Evolocumab | 105 | 14 |
| Jardiance | Empagliflozin | 101 | 20 |
| Ezetimibe | Ezetimibe | 72 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 69 | 14 |
| Rybelsus | Semaglutide | 69 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 63 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 58 | 16 |
| Memantine Hcl | Memantine Hcl | 55 | 13 |
| Potassium Chloride | Potassium Chloride | 55 | 18 |
| Torsemide | Torsemide | 55 | 18 |
| Pitavastatin Calcium | Pitavastatin Calcium | 52 | 15 |
| Trulicity | Dulaglutide | 51 | suppressed |
| Valsartan | Valsartan | 50 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 14 |
| Alprazolam | Alprazolam | 46 | 16 |
| Trazodone Hcl | Trazodone Hcl | 45 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 39 | 11 |
| Atorvastatin Calcium | Atorvastatin Calcium | 38 | 12 |
| Xyosted | Testosterone Enanthate | 37 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | 11 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 35 | suppressed |
| Carvedilol | Carvedilol | 34 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 33 | 12 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 31 | 15 |
| Eliquis | Apixaban | 31 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Invokana | Canagliflozin | 28 | suppressed |
| Praluent Pen | Alirocumab | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Gabapentin | Gabapentin | 26 | suppressed |
| Piroxicam | Piroxicam | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Omeprazole | Omeprazole | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 17 |
| Lisinopril | Lisinopril | 21 | suppressed |
| Livalo | Pitavastatin Calcium | 21 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Testosterone | Testosterone | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Niacin Er | Niacin | 15 | suppressed |
| Simvastatin | Simvastatin | 15 | suppressed |
| Progesterone | Progesterone, Micronized | 14 | suppressed |
| Aplenzin | Bupropion Hbr | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Dapsone | Dapsone | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $753.74 · 25 records | Amgen Inc. | APLENZIN, JARDIANCE, Kerendia, MOUNJARO, OTEZLA, REPATHA, SYNTHROID, UBRELVY, VRAYLAR, XYOSTED, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Aplenzin play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error